Please login to the form below

Not currently logged in
Email:
Password:

Horizon Discovery

This page shows the latest Horizon Discovery news and features for those working in and with pharma, biotech and healthcare.

Cell therapy disruptor Mogrify gains $3.7m in funding and a new leader

Cell therapy disruptor Mogrify gains $3.7m in funding and a new leader

Former Horizon chief Darrin Disley to lead the company through series A round. ... Darrin Disley (pictured below) is known in the industry for heading gene editing specialist Horizon Discovery, when he led the biotech from seed funding to a $113m IPO.

Latest news

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Cutting through the noise: CRISPR Cutting through the noise: CRISPR

    AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery. ... Rival platforms. CRISPR has certainly been seen as the most exciting gene-editing platform, and is being used very broadly across the

  • 30 Women Leaders in UK Healthcare 30 Women Leaders in UK Healthcare

    direct a team of around 150 scientists at the MSD UK Discovery Centre. ... In addition, she is a Non-Executive Director on the Board of Cambridge-based Horizon Discovery.

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    Other deals include an alliance with the UK biotech Immunocore via AZ's MedImmune subsidiary and an expansion of an existing personalised drug partnership with Horizon Discovery. ... Drug discovery and development is a team sport. You can't do it really

  • Deal Watch table for April 2013 Deal Watch table for April 2013

    392. Ambrx/ Astellas Pharma. Collaboration. Oncology discovery and development of novel antibody drug conjugates. ... 100. Horizon Discovery/ AstraZeneca. Collaboration. Kinase target programme, HD-001, as a means of developing novel therapies for

  • Pharma deals during April 2013 Pharma deals during April 2013

    This will enable the discovery of novel small molecules against multiple AZ targets in oncology, respiratory, cardiovascular, metabolism, infection and neuroscience. ... The third April “top 20” AZ deal is a collaboration with Horizon Discovery to

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Eric Rhodes becomes CEO of ERS Genomics Eric Rhodes becomes CEO of ERS Genomics

    Rhodes joins ERS Genomics from Horizon Discovery, where he served as senior vice president of research and development and chief technology officer. ... Prior to joining Horizon Discovery, Rhodes held a number of senior positions including director of

  • Jane Osbourn to chair BIA board Jane Osbourn to chair BIA board

    The new members of the board are Darrin Disley, chief executive of Horizon Discovery Group and David Hipkiss, chief business officer at Circassia Pharmaceuticals. Additionally Andrew Lightfood of Peptinnovate and Neil

  • Horizon Discovery appoints executive director Horizon Discovery appoints executive director

    David Smoller is chief business officer at the genomics firm. UK-based genetic research company Horizon Discovery has named Dr David Smoller as an executive director of the board. ... 1996. Horizon is a UK-based biotech focused on genomics research and

  • Horizon adds AZ’s Galbraith to board Horizon adds AZ’s Galbraith to board

    UK genomics company also appoints Susan Searle. Horizon Discovery has appointed two new board members, AstraZeneca's head of oncology R&D Susan Galbraith and Susan Searle, ex-CEO of Imperial ... We believe each will be an invaluable asset to Horizon, and

  • Horizon appoints board chair Horizon appoints board chair

    Dr Ian Gilham assumes position full-time. Horizon Discovery has appointed Dr Ian Gilham as chairman of its board of directors on a permanent basis after he spent several months as ... from his guidance as Horizon continues to develop as a world-leading

More from appointments
Approximately 3 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...

Infographics